GRIFOLS S A/S (NASDAQ:GRFS) has been assigned an average rating of “Hold” from the thirteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company.

A number of research firms recently issued reports on GRFS. Berenberg Bank restated a “buy” rating on shares of GRIFOLS S A/S in a research report on Tuesday, July 21st. HSBC upgraded GRIFOLS S A/S from a “reduce” rating to a “hold” rating in a research note on Tuesday, June 9th. ValuEngine cut GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Monday, August 24th. BidaskClub downgraded GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 25th. Finally, Zacks Investment Research cut shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, August 5th.

A number of large investors have recently bought and sold shares of GRFS. Two Sigma Advisers LP raised its stake in shares of GRIFOLS S A/S by 17.0% in the first quarter. Two Sigma Advisers LP now owns 388,700 shares of the biotechnology company’s stock valued at $7,828,000 after acquiring an additional 56,600 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of GRIFOLS S A/S by 33.2% during the first quarter. JPMorgan Chase & Co. now owns 660,551 shares of the biotechnology company’s stock worth $13,303,000 after buying an additional 164,526 shares in the last quarter. UBS Group AG increased its stake in shares of GRIFOLS S A/S by 223.4% during the second quarter. UBS Group AG now owns 137,588 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 95,041 shares during the period. BNP Paribas Arbitrage SA raised its holdings in GRIFOLS S A/S by 248.7% in the first quarter. BNP Paribas Arbitrage SA now owns 99,154 shares of the biotechnology company’s stock valued at $1,997,000 after acquiring an additional 70,716 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in GRIFOLS S A/S by 7.1% in the first quarter. Parametric Portfolio Associates LLC now owns 699,616 shares of the biotechnology company’s stock worth $14,090,000 after acquiring an additional 46,387 shares during the last quarter. Institutional investors own 17.98% of the company’s stock.

GRFS traded up $0.03 on Friday, reaching $16.65. 22,927 shares of the stock were exchanged, compared to its average volume of 1,154,565. The company’s 50-day moving average price is $17.22 and its 200 day moving average price is $19.13. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.86 and a quick ratio of 1.18. The firm has a market capitalization of $11.43 billion, a PE ratio of 18.56, a PEG ratio of 1.00 and a beta of 0.69. GRIFOLS S A/S has a fifty-two week low of $13.40 and a fifty-two week high of $25.73.

GRIFOLS S A/S (NASDAQ:GRFS) last issued its earnings results on Thursday, July 30th. The biotechnology company reported $0.35 EPS for the quarter, missing the Zacks’ consensus estimate of $0.37 by ($0.02). GRIFOLS S A/S had a net margin of 10.40% and a return on equity of 10.83%. The firm had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.46 billion. As a group, equities analysts forecast that GRIFOLS S A/S will post 1.29 earnings per share for the current fiscal year.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Featured Story: What is Liquidity?

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.